Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease
Vaccinex(VCNX) Newsfilter·2024-07-31 21:00Vaccinex(VCNX) Newsfilter·2024-07-31 21:00
R1Vaccinex(VCNX) Newsfilter·2024-07-31 21:00 R1Vaccinex(VCNX) Newsfilter·2024-07-31 21:00